338: Effect of CD3+ Cell Dose on Outcome in Patients after Conditioning Including Antithymocyte Globulin Followed by Un-Manipulated HLA-mismatched/haploidentical Blood and Marrow Transplantation
L. Dong,T. Wu,D. -P. Lu,M. . -J. Zhang,H. Chen,Z. Y. Gao,W. Han,Y. -C. Zhang,J. -B. Wang,Y. R. Liu
DOI: https://doi.org/10.1016/j.bbmt.2006.12.343
2007-01-01
Biology of Blood and Marrow Transplantation
Abstract:We investigated the potential correlation between the characteristics prior transplantation and the subsequent clinical outcomes in 175 consecutive patients who received HSC transplantation from HLA-mismatched/haploidentical donors. Patients eligible for study were those with a diagnosis of leukemia, all lacking an HLA matched sibling or unrelated donor. Patients ranged in age from 6 to 53 years (median 25 years) and donors from 13 to 66 years (median 40 years). Compatibility testing of family members included serology and intermediate resolution DNA typing for HLA-A, -B, and -C antigens, plus high resolution DNA typing for HLA-DRB1, -DQB1, and -DPB1. Donors included 72 mothers (41%), 29 fathers (16.6%), 54 siblings (31%), 16 children (9%), 4 cousins (2.3%), with various grades of HLA disparity: 28 (16%) with 1; 79 (45%) with 2; 68 (39%) with 3 antigen mismatch. Grafts (BM+PB) was harvested from donor BM collected after four days of G-CSF, and PB collected after 5 days of G-CSF. The graft was analyzed for content of CD34+ cells and subsets of lymphoid cell populations, CD3+, CD4+, CD8+, and CD14+, using standardized Multi-set kits (Becton-Dickinson, San Jose, CA, USA). All patients enrolled in this study were treated with a uniform conditioning regimen (BuCy2+ATG), given GVHD prophylaxis (CsA+ short term MTX), and followed from 36 to 1191days after transplantation (median 401 days). Univariate analysis for survival indicated that disease status prior transplantation and donor CD3+ cell dose were the only predictors of the 2-year probability of survival: early disease (77.8%), intermediate disease (38%), and those with advanced disease (52%), [P=0.018]; survival in those given a CD3+ cell dose <150 ×106/kg was 52% and CD3+ cell dose ≥150×106/kg was 74%, respectively [P=0.0215]. This was confirmed by multivariate analysis: patients transplanted with intermediate/advanced stage disease [RR=1.568 (95% CI, 1.128-2.17); P=0.007] had a worse overall survival; Infusion of a high dose of CD3+ cells (≥150 × 106/kg) had improved survival [0.530 (0.300-0.95); P=0.03] without increase the incidence of developing Grade 3-4 aGVHD [1.27 (0.58-2.76); P=0.56]. Our data have indicated that with the current protocol, patients given a relatively high dose of CD3+ cells (≥150×106/kg) have a significantly better overall survival after transplantation than those given lower doses of CD3+ cells (<150 ×106/kg).